Jump to content

Search the Community

Showing results for tags 'radium-223'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 6 results

  1. Jim Marshall (not a doctor) said ... Xofigo (Radium-223) has been recommended to go on the PBS. The conditions just published include: Previous Docetaxel, or unsuitability for Docetaxel; No previous enzalutamide (Xtandi) (or intolerance); No previous abiraterone (Zytiga) (or intolerance); So if a man has 2 or more bone metastases (mets) on the PBS his doctor will have to choose only one of: Xtandi (enzalutamide); Zytiga (abiraterone); Xofigo (Radium-233). If a man does not qualify for PBS Xofigo, doses cost about $7,000, with up to 6 doses the normal treatment. ... end Jim From the Public Summary Document – November 2017 PBAC Meeting Patients must have ≥ 2 skeletal metastases AND Patient must have a WHO performance status of 2 or less AND Patient must have failed treatment with docetaxel due to resistance or intolerance; OR Patient must be unsuitable for docetaxel treatment on the basis of predicted intolerance to docetaxel AND The treatment must not be used in combination with chemotherapy. AND The patient must not receive PBS-subsidised 223Ra if progressive disease develops while on 223Ra AND The patient must not have received prior treatment with abiraterone or enzalutamide; OR The patient must have developed intolerance to enzalutamide requiring permanent withdrawal AND The patient must have developed intolerance to abiraterone requiring permanent withdrawal.
  2. During the phone-in meeting we held this morning (23 March 2018), there was discussion about Xofigo (Radium-223). The question arose of whether Xofigo gave both pain relief and longer survival. During that discussion, I mentioned that I had discussed Xofigo with American Medical Oncologist Alicia Morgans, and that this was on video. This is the video: A report on the ALSYMPCA trial of Xofigo (Radium-223) (previously called Alpharadin) can be found here. http://www.nejm.org/doi/full/10.1056/NEJMoa1213755 You can find all our videos on our YouTube channel: YouTube.com/JimJimJimJim Jim
  3. There are two committees that recommend public expenditure on medical treatments in Australia - the Medical Services Advisory Committee (MSAC) and the Pharmaceutical Benefits Advisory Committee (PBAC). The MSAC approved the use of Xofigo for prostate cancer patients in 2014. The PBAC announced approval of Xofigo for prostate cancer patients today (15 December 2017). The delays were due in part to this being the first treatment that needs to be paid for by both Medicare and the PBS. New rules had to be made. Ministerial approval can be expected in the near future, and men who need this treatment for prostate cancer in the bones will be able to get it. Many of our members sent submissions to both the MSAC and the PBAC, and I am convinced that had a big part to play in the result. Members should know that although I fronted this campaign, speaking to parliamentary lunches, and to public meetings and parliamentarians in marginal electorates, and making the videos, all Executive Committee members contributed to the campaign, and that one, the late Paul Hobson, was the real driving force behind this result. Thanks go to all who contributed. Jim Marshall Convenor Australian Advanced Prostate Cancer Support Group
  4. As you probably know, we have been campaigning to have the advanced prostate cancer treatment Xofigo (Radium-223) made available under Medicare for Australian men. As part of this, this week our Convenor, Jim Marshall (JimJimJimJim), will speak on this at events in Biloela and Nowra. Hosts in Biloela will be Ken O'Dowd MP, Member for Flynn, Qld and Biloela Mens Shed. Hosts in Nowra will be Ann Sudmalis MP, Member for Gilmore, NSW and the Bomaderry Advanced Prostate Men’s Group. Prostate Cancer Foundation of Australia (PCFA) CEO, Anthony Lowe, will also speak, and local media will be invited to interview the speakers after the event. Other people involved in organising these events include: Geoff Lester-PCFA Ambassador Gladstone Rockhampton Prostate Cancer Support Group Judy Cornick- Prostate Cancer Specialist Nurse Rockhampton Lloyd Younger- PCFA Ambassador Rockhampton Leigh Bowman -Shoalhaven Prostate Cancer Support Group Evan Kallipolitis, PCFA Community Engagement On this journey, Jim will stop at Gladstone on the nights of Tuesday 4 April 2017 and Wednesday 5 April, and in Sydney on the nights of Thursday 6 April 2017 and Friday 7 April 2017. If you would like to meet Jim and have a chat in Gladstone or in Woolloomooloo, just reply to this email. Jim would also like to meet anyone who can make it to the Biloela or Nowra events, but pressure of the event timetables mean long chats are unlikely on event days. The Biloela event Wednesday 5 April 2017 10:00 AM Callide Valley Men’s Shed, Valentine Plains Rd, Biloela QLD 4715 The Nowra event Friday 7 April 2017 9:30 AM Nowra Golf Club, Fairway Dr North Nowra NSW 2541 If you haven't yet seen the Xofigo (Radium-223) video yet, it's here: Jim had last week off in Caloundra, and Cyclone Debbie was the main feature. Jim's travel plans above may also be affected by the aftermath of Debbie.
  5. Xofigo is a treatment which can both extend life and relieve pain in advanced prostate cancer. Expert advisers have agreed it is effective. Expert advisers have agreed the price is right. But men who need it can still not get Xofigo on Medicare. Watch this video to find out why this tragedy is happening, and what you can do about it today. The video is 5 minutes long and has closed captions (Cc) for the hard of hearing. Jim
  6. Click here to read "A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer" by Joel Nowak of Malecare. Radium 223 (Xofigo) has been approved for use in Australia. However it is not publicly subsidised. This means that its cost effectively puts it out of reach of most Australian men with advanced prostate cancer. Your committee is lobbying to try to get Radium 223 (Xofigo) publicly subsidised. However it's unlikely to be publicly subsidised in the near future.
  • Create New...